Predictors of Psilocybin Use Intentions in US Mental Health Care

Demographic and Psychological Predictors of Psilocybin Use Intentions

Recent research published in September 2026 (OpenAlex W7204955117) provides the most detailed analysis to date of the factors influencing individuals’ intentions to use psilocybin for mental health treatment in the United States. The study, which surveyed over 1,100 participants, found that willingness to use psilocybin is significantly lower than willingness to use psychotherapy or traditional psychiatric medications. Key predictors of openness to psilocybin included younger age, male gender, higher self-reported mindfulness, elevated narcissism, and the presence of current depressive symptoms. These findings suggest that attitudes toward psilocybin are shaped by both demographic and psychological profiles, which may have direct consequences for clinical trial recruitment and eventual patient populations.

Preference for Natural Over Synthetic Psilocybin Formulations

The study’s second phase revealed a robust preference for natural psilocybin—specifically, compounds isolated directly from mushrooms—compared to chemically identical synthetic versions or synthetic analogs. This preference persisted even when participants were informed that all forms produced the same biological effects. Such attitudes mirror trends seen in other areas of medicine and nutrition, where perceived ‘naturalness’ can outweigh scientific equivalence in shaping consumer behavior. This insight is particularly relevant for pharmaceutical developers, as it signals a potential barrier to adoption for synthetic psilocybin products, despite their manufacturing and regulatory advantages.

Implications for Clinical Trials and Policy Development

The identification of demographic and psychological predictors of psilocybin use intentions has immediate implications for ongoing and future clinical trials. Recruitment strategies may need to account for lower baseline interest among older adults and women, as well as the heightened openness among individuals reporting depressive symptoms. Additionally, the strong preference for natural formulations suggests that trial designs and informed consent processes should transparently address the source of the psilocybin used, as this could influence both recruitment and retention. From a policy perspective, regulators and public health agencies may need to anticipate disparities in access or demand based on these preferences, particularly if only synthetic formulations are approved or reimbursed.

• Recruitment Considerations: Trial sponsors may face challenges enrolling representative samples if certain demographics are less willing to participate in psilocybin studies.
• Messaging and Education: Public health campaigns may need to address misconceptions about synthetic versus natural compounds to ensure equitable uptake and informed decision-making.
• Market Positioning: Pharmaceutical companies developing synthetic psilocybin may need to consider patient education or branding strategies that bridge the preference gap for natural products.

Risks, Unknowns, and a Real-World Failure Mode

While the study provides valuable insights, it also highlights several risks and unknowns. First, stated intentions do not always translate into real-world behavior, especially when access is contingent on regulatory approval, insurance coverage, and provider willingness. Furthermore, the strong preference for natural psilocybin could inadvertently drive some patients toward unregulated or illicit sources if only synthetic options are available—mirroring a failure mode seen in medical cannabis markets, where regulatory supply does not match patient demand for specific formulations. Another unknown is how these preferences will evolve as more clinical data and real-world evidence accumulate, or as direct-to-consumer marketing shapes public perceptions.

Looking Ahead: Research and Policy Directions

As psilocybin approaches possible US Food and Drug Administration (FDA) review for mental health indications, understanding patient attitudes is no longer a theoretical exercise. Future research should investigate how these preferences interact with clinical outcomes, side effect profiles, and long-term adherence. Policymakers and industry stakeholders will need to balance scientific evidence, regulatory feasibility, and patient values in shaping access frameworks. Notably, the study’s nuanced findings challenge the assumption that therapeutic innovation alone will drive adoption; instead, patient-centered design and transparent communication may prove just as critical to the responsible integration of psychedelics into mental health care.

Authored by Dr. Jamie L. Carter, PhD (Behavioral Science Editor). Reviewed by Dr. Alex Nguyen, MD, September 2026. Research sourced directly from OpenAlex W7204955117 and primary FDA and trial registry documents.